CN103808937B - 用于乳腺癌早中期快速诊断试剂盒及其检测方法 - Google Patents
用于乳腺癌早中期快速诊断试剂盒及其检测方法 Download PDFInfo
- Publication number
- CN103808937B CN103808937B CN201410093761.6A CN201410093761A CN103808937B CN 103808937 B CN103808937 B CN 103808937B CN 201410093761 A CN201410093761 A CN 201410093761A CN 103808937 B CN103808937 B CN 103808937B
- Authority
- CN
- China
- Prior art keywords
- antibody
- breast cancer
- microtiter plate
- preparation
- capture antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 56
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 53
- 238000001514 detection method Methods 0.000 title claims abstract description 36
- 238000003745 diagnosis Methods 0.000 title claims abstract description 28
- 230000031864 metaphase Effects 0.000 title claims abstract description 23
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 22
- 229930182830 galactose Natural products 0.000 claims abstract description 21
- -1 aspartyl Chemical group 0.000 claims abstract description 20
- 101710186708 Agglutinin Proteins 0.000 claims abstract description 19
- 101710146024 Horcolin Proteins 0.000 claims abstract description 19
- 101710189395 Lectin Proteins 0.000 claims abstract description 19
- 101710179758 Mannose-specific lectin Proteins 0.000 claims abstract description 19
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims abstract description 19
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims abstract description 19
- 239000000910 agglutinin Substances 0.000 claims abstract description 19
- 239000000427 antigen Substances 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 32
- 241000124008 Mammalia Species 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 210000004962 mammalian cell Anatomy 0.000 claims description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 9
- 238000013016 damping Methods 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 108010001517 Galectin 3 Proteins 0.000 description 24
- 102000000802 Galectin 3 Human genes 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 17
- 239000000523 sample Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- ICLWKKKAGOALPU-UHFFFAOYSA-N 2-(3,5-dimethylphenyl)-4,6-dimethylaniline Chemical compound CC1=C(C(=CC(=C1)C)C1=CC(=CC(=C1)C)C)N ICLWKKKAGOALPU-UHFFFAOYSA-N 0.000 description 2
- 102000044445 Galectin-8 Human genes 0.000 description 2
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010029174 Nerve compression Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000901030 Homo sapiens Aspartyl/asparaginyl beta-hydroxylase Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N beta-keto-glutaric acid Natural products OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010090623 galactose binding protein Proteins 0.000 description 1
- 102000021529 galactose binding proteins Human genes 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/365—Breast disorders, e.g. mastalgia, mastitits, Paget's disease
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410093761.6A CN103808937B (zh) | 2014-03-13 | 2014-03-13 | 用于乳腺癌早中期快速诊断试剂盒及其检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410093761.6A CN103808937B (zh) | 2014-03-13 | 2014-03-13 | 用于乳腺癌早中期快速诊断试剂盒及其检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103808937A CN103808937A (zh) | 2014-05-21 |
CN103808937B true CN103808937B (zh) | 2015-11-18 |
Family
ID=50706011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410093761.6A Expired - Fee Related CN103808937B (zh) | 2014-03-13 | 2014-03-13 | 用于乳腺癌早中期快速诊断试剂盒及其检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103808937B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128082A2 (en) * | 2005-05-26 | 2006-11-30 | The Johns Hopkins University | Biomarkers for breast cancer |
WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
WO2012141285A1 (ja) * | 2011-04-15 | 2012-10-18 | ジェイファーマ株式会社 | 乳癌のバイオマーカー |
CN103592444A (zh) * | 2013-11-27 | 2014-02-19 | 中国人民解放军沈阳军区总医院 | 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法 |
-
2014
- 2014-03-13 CN CN201410093761.6A patent/CN103808937B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128082A2 (en) * | 2005-05-26 | 2006-11-30 | The Johns Hopkins University | Biomarkers for breast cancer |
WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
WO2012141285A1 (ja) * | 2011-04-15 | 2012-10-18 | ジェイファーマ株式会社 | 乳癌のバイオマーカー |
CN103592444A (zh) * | 2013-11-27 | 2014-02-19 | 中国人民解放军沈阳军区总医院 | 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103808937A (zh) | 2014-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106405104B (zh) | 一种新的肝硬化或肝纤维化标志物 | |
JP6018923B2 (ja) | 敗血症の予後の予測方法 | |
CN109342727B (zh) | 食管鳞状细胞癌自身抗体分子标志物模型及其应用 | |
CN104316685B (zh) | 一种二乙酰精胺的检测试剂盒及制备方法和应用 | |
Feng et al. | Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumour invasiveness | |
CN102759623A (zh) | 一种检测ngal胶体金试纸条及其制备方法 | |
CN105759057A (zh) | 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法 | |
CN103954761B (zh) | 用于卵巢癌早中期快速诊断试剂盒及其检测方法 | |
CN113607948A (zh) | 检测血清中Glypican-1蛋白含量在评价胰腺癌发生发展和分期判断中的应用 | |
Jia et al. | Prognostic correlation between MFG-E8 expression level and colorectal Cancer | |
CN110726846B (zh) | Hbp蛋白作为川崎病的诊断标志物的应用 | |
CN106501517B (zh) | 检测血清中sparc蛋白的物质在制备筛查肝细胞癌试剂盒中的应用 | |
CN107677824A (zh) | 用于卵巢癌早中期快速诊断化学发光试剂盒 | |
CN103808937B (zh) | 用于乳腺癌早中期快速诊断试剂盒及其检测方法 | |
CN107703303A (zh) | 用于乳腺癌早中期快速诊断化学发光试剂盒 | |
CN103969437B (zh) | 用于卵巢癌早中期快速诊断试剂盒的制备方法 | |
CN106950376A (zh) | 用于肺癌早中期快速诊断化学发光试剂盒 | |
CN103823066A (zh) | 用于肺癌早中期快速诊断试剂盒及其检测方法 | |
CN109085355A (zh) | 血清蛋白标志物组合在肺癌筛查和诊治中的应用 | |
CN105037534B (zh) | 一种检测肺癌标志物myc抗原表位氨基酸序列及应用 | |
EP2793028B1 (en) | Thioredoxin-1 as diagnostic marker for ovarian cancer | |
CN106596939B (zh) | 用于肝癌体外诊断试剂盒及其检测方法 | |
Hafez et al. | Alfa-fetoprotein L3 subfraction and osteopontin: novel markers for the diagnosis of hepatocellular carcinoma | |
CN105954517B (zh) | 一种肺癌筛查试剂盒 | |
CN106405116A (zh) | 用于胃癌诊断试剂盒及其检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Kit for rapid diagnosis of early-to-mid breast cancers and detection method of kit Effective date of registration: 20191012 Granted publication date: 20151118 Pledgee: Bank of China Limited by Share Ltd. Guangzhou Panyu branch Pledgor: GUANGZHOU HENGTAI BIOTECHNOLOGY CO.,LTD. Registration number: Y2019440000108 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201204 Granted publication date: 20151118 Pledgee: Bank of China Limited by Share Ltd. Guangzhou Panyu branch Pledgor: GUANGZHOU HENGTAI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2019440000108 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Rapid diagnostic kit for early and middle stage breast cancer and its detection method Effective date of registration: 20201208 Granted publication date: 20151118 Pledgee: Bank of China Limited by Share Ltd. Guangzhou Panyu branch Pledgor: GUANGZHOU HENGTAI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020440000389 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220927 Granted publication date: 20151118 Pledgee: Bank of China Limited by Share Ltd. Guangzhou Panyu branch Pledgor: GUANGZHOU HENGTAI BIOTECHNOLOGY CO.,LTD. Registration number: Y2020440000389 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Rapid diagnostic kit for early and middle stage of breast cancer and its detection method Effective date of registration: 20221014 Granted publication date: 20151118 Pledgee: Bank of China Limited by Share Ltd. Guangzhou Panyu branch Pledgor: GUANGZHOU HENGTAI BIOTECHNOLOGY CO.,LTD. Registration number: Y2022980018084 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151118 |
|
CF01 | Termination of patent right due to non-payment of annual fee |